1. Home
  2. UHAL vs NNNN Comparison

UHAL vs NNNN Comparison

Compare UHAL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UHAL
  • NNNN
  • Stock Information
  • Founded
  • UHAL 1945
  • NNNN 2021
  • Country
  • UHAL United States
  • NNNN Germany
  • Employees
  • UHAL N/A
  • NNNN N/A
  • Industry
  • UHAL Rental/Leasing Companies
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • UHAL Consumer Discretionary
  • NNNN Health Care
  • Exchange
  • UHAL Nasdaq
  • NNNN Nasdaq
  • Market Cap
  • UHAL N/A
  • NNNN 267.7M
  • IPO Year
  • UHAL N/A
  • NNNN 2025
  • Fundamental
  • Price
  • UHAL $63.82
  • NNNN $6.43
  • Analyst Decision
  • UHAL
  • NNNN
  • Analyst Count
  • UHAL 0
  • NNNN 0
  • Target Price
  • UHAL N/A
  • NNNN N/A
  • AVG Volume (30 Days)
  • UHAL 74.8K
  • NNNN 28.8K
  • Earning Date
  • UHAL 05-28-2025
  • NNNN 01-01-0001
  • Dividend Yield
  • UHAL N/A
  • NNNN N/A
  • EPS Growth
  • UHAL N/A
  • NNNN N/A
  • EPS
  • UHAL 2.29
  • NNNN 0.06
  • Revenue
  • UHAL $5,691,148,000.00
  • NNNN $8,185,146.00
  • Revenue This Year
  • UHAL $3.69
  • NNNN N/A
  • Revenue Next Year
  • UHAL $3.74
  • NNNN N/A
  • P/E Ratio
  • UHAL $27.77
  • NNNN $118.17
  • Revenue Growth
  • UHAL N/A
  • NNNN 21.95
  • 52 Week Low
  • UHAL $56.28
  • NNNN $5.18
  • 52 Week High
  • UHAL $79.04
  • NNNN $7.82
  • Technical
  • Relative Strength Index (RSI)
  • UHAL 54.21
  • NNNN N/A
  • Support Level
  • UHAL $62.19
  • NNNN N/A
  • Resistance Level
  • UHAL $65.10
  • NNNN N/A
  • Average True Range (ATR)
  • UHAL 1.59
  • NNNN 0.00
  • MACD
  • UHAL 0.54
  • NNNN 0.00
  • Stochastic Oscillator
  • UHAL 78.88
  • NNNN 0.00

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: